CORT: Corcept Therapeutics Incorporated - Summary | Jitta

Corcept Therapeutics Incorporated

NASDAQ:CORT

Price
$21.85
Loss Chance
44.2%
5.63JITTA SCORE
21.02%Under Jitta Line
Jitta Ranking
255 / 1,181
2,464 / 4,991
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (62)
Recent Business Performance (41)
Financial Strength (79)
Return to Shareholders (55)
Competitive Advantage (63)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Debt LevelLow Long Term Debt
Return on EquityConsistently High
CapExVery Low
Cash Conversion CycleLess than 30 days
Operating MarginDeclined
Recent Business PerformanceEarning decline 37.84% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
5.63
21.02%
1.92
83.86%
1.95
183.64%
Pharmaceuticals
6.58
35.50%
2.84
95.98%
4.79
37.35%
COMPANY DESCRIPTION
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.